Integra LifeSciences (NASDAQ:IART) Downgraded by Wall Street Zen to “Hold”

Wall Street Zen cut shares of Integra LifeSciences (NASDAQ:IART) from a buy rating to a hold rating in a report released on Saturday,Wall Street Zen reports.

Several other brokerages have also weighed in on IART. Weiss Ratings raised Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, August 14th. BMO Capital Markets started coverage on shares of Integra LifeSciences in a research report on Wednesday, July 8th. They set a “market perform” rating and a $19.00 price target for the company. Argus raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 price objective on the stock in a report on Thursday, June 18th. UBS Group began coverage on shares of Integra LifeSciences in a research note on Tuesday, July 28th. They set a “neutral” rating and a $19.00 target price for the company. Finally, Wells Fargo & Company raised their price target on shares of Integra LifeSciences from $15.00 to $18.00 and gave the company an “equal weight” rating in a research note on Thursday, July 30th. One analyst has rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Reduce” and an average target price of $18.43.

Integra LifeSciences Stock Performance

Shares of IART stock opened at $12.68 on Friday. The company has a quick ratio of 2.11, a current ratio of 3.60 and a debt-to-equity ratio of 1.75. The business has a 50 day moving average of $16.69 and a two-hundred day moving average of $15.15. Integra LifeSciences has a 52 week low of $8.70 and a 52 week high of $20.49. The company has a market cap of $986.12 million, a P/E ratio of -140.87, a PEG ratio of 0.65 and a beta of 1.21.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings results on Wednesday, July 29th. The life sciences company reported $0.56 earnings per share for the quarter, topping analysts’ consensus estimates of $0.48 by $0.08. The business had revenue of $418.76 million for the quarter, compared to analysts’ expectations of $417.54 million. Integra LifeSciences had a positive return on equity of 18.30% and a negative net margin of 0.44%.Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. As a group, analysts anticipate that Integra LifeSciences will post 2.45 EPS for the current year.

Institutional Investors Weigh In On Integra LifeSciences

A number of hedge funds and other institutional investors have recently modified their holdings of IART. Paradigm Capital Management Inc. NY bought a new stake in shares of Integra LifeSciences during the 2nd quarter worth about $61,766,000. Hsbc Holdings PLC bought a new position in shares of Integra LifeSciences in the fourth quarter valued at approximately $879,000. Bank of New York Mellon Corp bought a new position in shares of Integra LifeSciences in the second quarter valued at approximately $8,723,000. Louisiana State Employees Retirement System acquired a new position in shares of Integra LifeSciences during the first quarter valued at approximately $280,000. Finally, Maverick Capital Ltd. acquired a new position in shares of Integra LifeSciences during the first quarter valued at approximately $679,000. 84.78% of the stock is currently owned by institutional investors.

Trending Headlines about Integra LifeSciences

Here are the key news stories impacting Integra LifeSciences this week:

• Positive Sentiment: Integra expects to generate strong cash flow despite the disruption, while the proposed seven-year, $600 million Senior Secured Term Loan B could improve liquidity and refinance existing obligations. Integra LifeSciences Announces Launch of $600 Million Senior Secured Term Loan B
• Neutral Sentiment: Preliminary third-quarter adjusted EPS guidance is $0.55-$0.59, broadly in line with the $0.56 analyst consensus, suggesting the immediate-quarter impact may be manageable. Truist also upgraded the shares to a “Hold,” indicating a more balanced view rather than a bullish recommendation. Integra LifeSciences Announces Preliminary Third Quarter Results and Updates Full-Year 2026 Guidance
• Negative Sentiment: Integra reduced its 2026 revenue forecast to $1.634 billion-$1.654 billion from $1.654 billion-$1.695 billion. Full-year EPS guidance was lowered to $2.30-$2.40 from $2.40-$2.50, below the $2.46 consensus estimate. The cuts reflect production interruptions and millions of dollars in costs associated with the Cincinnati flooding. Integra LifeSciences Lowers Revenue and Earnings Outlook for 2026
• Negative Sentiment: The $600 million debt refinancing may support operations, but it also raises concerns about borrowing costs and leverage, particularly as profitability is being reduced by the flood-related disruption. The combination of lower guidance, facility uncertainty and additional secured debt explains why IART shares have decreased sharply and traded at unusually high volume. Integra Lowers FY26 Forecast Following Cincinnati Flood; Plans $600M Debt Refinance

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, and orthopedic procedures. Its offerings are designed to help physicians treat neurological conditions, traumatic injuries, complex wounds, and other surgical needs.

The company’s products include dural repair and regeneration materials, cerebrospinal fluid management systems, surgical instruments, nerve and tendon repair products, and tissue-engineered solutions for wound care and reconstructive surgery.